TABLE 1.
Clinical characteristics and flow cytometric profiles of HLA-A*24:02+ ACs and ATL patients examined in this studya
| Patient ID | Age (yr) | Sex | Clinical status | No. of WBCs (/μl) | Lymphocytes (%) | Atypical lymphocytes (%) | No. of provirus DNA copies (PVL)/100 PBMCs | sIL-2R (U/ml) | HAS flow prolife |
Tax-Tet (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CADM1−, P (%) | CADM1+ |
||||||||||||
| D (%) | N (%) | D + N (%) | |||||||||||
| AC1 | 48 | Female | sAC | 3,780 | 32.0 | 0.5 | 1.61 | 416 | 91.8 | 1.8 | 1.0 | 2.8 | 20.10 |
| AC2 | 46 | Female | sAC | 7,280 | 28.0 | 0 | 0.65 | 239 | 80.8 | 0.2 | 0.1 | 0.3 | 1.05 |
| AC3 | 63 | Male | sAC | 4,570 | 39.0 | 0 | 0.94 | 311 | 92.2 | 2.2 | 0.7 | 2.9 | 2.76 |
| AC4 | 56 | Female | sAC | 5,020 | 42.0 | 0 | 0.50 | 305 | 90.2 | 2.6 | 0.8 | 3.4 | 2.07 |
| AC5 | 58 | Male | sAC | 3,850 | 36.5 | 0.5 | 0.05 | 364 | 94.8 | 1.1 | 0.2 | 1.3 | 1.76 |
| AC6 | 61 | Female | sAC | 4,220 | 32.5 | 0 | 0.57 | 327 | 85.0 | 0.2 | 0.1 | 0.3 | 0.66 |
| AC7 | 53 | Female | sAC | 6,940 | 33.0 | 0.5 | 0.06 | 220 | 86.6 | 1.1 | 0.3 | 1.4 | 1.75 |
| AC8 | 49 | Female | sAC | 3,560 | 23.0 | 0.5 | 0.04 | 207 | 86.2 | 0.1 | 0.1 | 0.2 | 0.14 |
| AC9 | 71 | Male | sAC | 5,200 | 30.5 | 0.5 | 1.37 | 272 | 79.9 | 2.5 | 1.9 | 4.4 | 0.05 |
| AC10 | 43 | Male | sAC | 5,710 | 43.5 | 0 | 0.22 | 277 | 95.9 | 0.7 | 0.1 | 0.9 | 3.37 |
| AC12 | 56 | Female | sAC | 10,300 | 21.5 | 0.5 | 0.97 | 462 | 77.0 | 0.5 | 0.5 | 1.0 | 1.59 |
| AC13 | 70 | Male | sAC | 3,810 | 37.0 | 0 | 1.93 | 435 | 81.7 | 0.7 | 0.3 | 1.0 | 0.83 |
| AC14 | 67 | Female | sAC | 5,540 | 23.5 | 1.0 | 1.00 | 657 | 82.5 | 0.4 | 0.3 | 0.8 | 6.60 |
| AC15 | 52 | Female | sAC | 5,400 | 28.0 | 1.5 | 0.29 | 264 | 87.2 | 0.2 | 0.1 | 0.3 | 0.44 |
| AC11 | 63 | Male | hrAC | 6,070 | 25.0 | 1.0 | 5.26 | 378 | 71.1 | 7.1 | 6.0 | 13.1 | 3.12 |
| AC16 | 66 | Female | hrAC | 5,590 | 45.0 | 5.3 | 14.31 | 381 | 71.6 | 5.2 | 19.3 | 24.5 | 0.71 |
| AC17 | 56 | Male | hrAC | 8,780 | 32.0 | 1.0 | 17.53 | 700 | 50.0 | 27.2 | 19.0 | 46.2 | 2.53 |
| cATL1 | 60 | Male | ATL (chronic type) | 9,850 | 12.5 | 57.5 | 83.17 | 4,560 | 1.3 | 53.5 | 44.7 | 98.2 | 3.47 |
| aATL1 | 58 | Female | ATL (acute type) | 51,200 | 1.5 | 96.0 | 280.25 | 29,600 | 0.3 | 0.3 | 99.2 | 99.5 | UD |
| aATL2* | 57 | Male | ATL (acute type) | 1,430 | 18.0 | 0 | 25.2 | 900 | NA | NA | NA | NA | UD |
| aATL3* | 54 | Male | ATL (lymphoma type) | 1,270 | 54 | 5 | NA | 982 | NA | NA | NA | NA | 1.97 |
| aATL4 | 55 | Male | ATL(lymphoma type) | 1,310 | 25 | 1 | NA | 817 | NA | NA | NA | NA | 0.08 |
ID, identifier; WBCs, white blood cells; sIL-2R, soluble interleukin 2 receptor; AC, asymptomatic HTLV-1 carrier; sAC, asymptomatic HTLV-1 carrier without high risk of ATL development defined by the PVL (fewer than 4 copies of proviruses per 100 PBMCs); hrAC, high-risk asymptomatic HTLV-1 carrier who had more than 4 copies of proviruses per 100 PBMCs; cATL, chronic-type ATL; aATL, acute-type ATL; HAS flow profiles, distribution to the three subpopulations P (CADM1− CD7+), D (CADM1+ CD7dim), and N (CADM1+ CD7−) by plot of CADM1 versus CD7 for CD4+ cells in PB samples by flow cytometry; Tax-Tet (%), the proportion of Tax301-309/HLA tetramer-reacting cells to total CD8T cells in PB; NA, not analyzed; UD, under the detection limits. The clinical data for WBCs, lymphocytes, atypical lymphocytes, PVL, and sIL-2R were measured using samples that were obtained at a time close to the point of collecting samples for the other experiments. Furthermore, the clinical data and Tax-Tet (%) of these two patients were used as samples before allo-HSCT in a preceding study (19).